Claims for Patent: 10,849,889

Summary for Patent: 10,849,889

Title:	Methods of treating Fabry patients having renal impairment
Abstract:	Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in .alpha.-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
Inventor(s):	Castelli; Jeff (New Hope, PA), Benjamin; Elfrida (Millstone Township, NJ)
Assignee:	Amicus Therapeutics, Inc. (Cranbury, NJ)
Application Number:	16/817,877
Patent Claims:	1. A method of stabilizing renal function in an enzyme replacement therapy (ERT)-experienced patient diagnosed with Fabry disease and having renal impairment, the method comprising: a. administering to the patient an effective amount of migalastat at a frequency of once every other day, and b. reducing globotriaosylceramide (GL-3) accumulated in the patient's organs, wherein the effective amount is about 100 mg to about 150 mg free base equivalent (FBE), wherein the administration of the migalastat is effective to stabilize renal function in the patient and wherein the patient has a HEK assay amenable mutation in .alpha.-galactosidase A. 2. The method of claim 1, wherein the organs comprise the kidney and heart. 3. The method of claim 1, wherein the organs comprise the kidney, heart, and liver. 4. The method of claim 2, wherein the patient has mild renal impairment with an eGFR of 60 to 90 mL/min/1.73 m.sup.2. 5. The method of claim 2, wherein the patient has moderate renal impairment with an eGFR of 30 to 59 mL/min/1.73 m.sup.2. 6. The method of claim 2, wherein the patient has severe renal impairment with an eGFR of less than 30 mL/min/1.73 m.sup.2. 7. The method of claim 2, wherein the patient has a proteinuria level of less than 100 mg/24 hr prior to initiating the administration of the migalastat. 8. The method of claim 2, wherein the patient has a proteinuria level of 100 to 1,000 mg/24 hr prior to initiating the administration of the migalastat. 9. The method of claim 2, wherein the patient has a proteinuria level of greater than 1,000 mg/24 hr prior to initiating the administration of the migalastat. 10. The method of claim 2, wherein the migalastat is administered for at least 28 days. 11. The method of claim 2, wherein the migalastat is administered for at least 6 months. 12. The method of claim 2, wherein the migalastat is administered for at least 12 months. 13. The method of claim 2, wherein the migalastat is in a solid dosage form. 14. The method of claim 13, wherein the migalastat is administered orally. 15. The method of claim 2, wherein the subject has mild renal impairment, and wherein administration of the migalastat provides a reduction in kidney interstitial capillary GL-3 inclusions of about 0.30. 16. The method of claim 2, wherein the HEK assay amenable mutation is a mutation that, when the mutation is expressed in HEK-293 cells incubated in the presence of 10 .mu.M migalastat compared to HEK-293 cells without migalastat, is shown to have (1) a relative increase of at least 20% .alpha.-galactosidase A activity and (2) an absolute increase of at least 3% of the wild-type .alpha.-galactosidase A activity. 17. The method of claim 16, further comprising determining that the patient has the HEK assay amenable mutation and then administering the migalastat to the patient. 18. The method of claim 1, wherein the migalastat is administered as migalastat free base. 19. The method of claim 1, wherein the migalastat is administered as a pharmaceutically acceptable salt. 20. A method of stabilizing renal function in enzyme replacement therapy (ERT)-experienced Fabry disease patients, wherein the method comprises administering, to a group of Fabry disease patients having renal impairment and a HEK assay amenable .alpha.-galactosidase A mutation, about 100 mg to about 150 mg free base equivalent (FBE) of migalastat, wherein the administration is effective to (i) provide a mean decrease in globotriaosylceramide (GL-3) in the kidneys of the patients and (ii) provide a mean annualized rate of change in eGFR.sub.CKD-EPI of greater than -1.0 mL/min/1.73 m.sup.2. 21. The method of claim 20, wherein the group of patients have moderate renal impairment with an eGFR of 30 to 59 mL/min/1.73 m.sup.2, and wherein the administration is effective to provide a mean reduction in kidney interstitial capillary GL-3 inclusions of about 0.39. 22. The method of claim 20, wherein the group of patients have mild renal impairment with an eGFR of 60 to 90 mL/min/1.73 m.sup.2, and wherein the administration is effective to provide a mean reduction in kidney interstitial capillary GL-3 inclusions of about 0.30. 23. The method of claim 20, wherein the HEK assay amenable mutation is a mutation that, when the mutation is expressed in HEK-293 cells incubated in the presence of 10 .mu.M migalastat compared to HEK-293 cells without migalastat, is shown to have (1) a relative increase of at least 20% .alpha.-galactosidase A activity and (2) an absolute increase of at least 3% of the wild-type .alpha.-galactosidase A activity. 24. The method of claim 20, wherein the migalastat is administered as migalastat free base. 25. The method of claim 20, wherein the migalastat is administered as a pharmaceutically acceptable salt. 26. A method of stabilizing renal function in a patient diagnosed with Fabry disease and having renal impairment, the method comprising: administering to the patient about 100 mg to about 150 mg free base equivalent (FBE) of migalastat at a frequency of once every other day, and reducing globotriaosylceramide (GL-3) accumulated in the patient's kidney and heart, wherein the administration of the migalastat is effective to stabilize renal function in the patient, wherein the patient has a HEK assay amenable mutation in .alpha.-galactosidase A, wherein the HEK assay amenable mutation is a mutation that, when the mutation is expressed in HEK-293 cells incubated in the presence of 10 .mu.M migalastat compared to HEK-293 cells without migalastat, is shown to have (1) a relative increase of at least 20% .alpha.-galactosidase A activity and (2) an absolute increase of at least 3% of the wild-type .alpha.-galactosidase A activity, wherein the patient is an enzyme replacement therapy (ERT)-experienced patient, and wherein the patient has a proteinuria level of 100 to 1,000 mg/24 hr prior to initiating the administration of the migalastat. 27. The method of claim 26, wherein the migalastat is administered as migalastat free base. 28. The method of claim 26, wherein the migalastat is administered as a pharmaceutically acceptable salt.